Last reviewed · How we verify
SKB518
At a glance
| Generic name | SKB518 |
|---|---|
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors (PHASE2)
- A Study of SKB518 in Patients With Lung Cancer (PHASE2)
- A Study of SKB518 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SKB518 CI brief — competitive landscape report
- SKB518 updates RSS · CI watch RSS
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. portfolio CI